Covid Apollo Project Makes Investment in Rhinostics to Accelerate Covid-19 Testing Volumes Through High Throughput Sample Accessioning
In a Series A round, Covid Apollo announces its investment in Rhinostics, an early-stage company that provides a novel solution of enabling comfortable sample collection, rapid accessioning, and automated cap removal that can be linked to high throughput Covid-19 assays to remove wasted time, headcount and costs from laboratory workflows.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005325/en/
Revolutionizing Laboratory Workflows. The RHINOstic automated nasal swab seamlessly integrates rapid sample accessioning and decapping with rapid assay worklows. (Photo: Business Wire)
The Covid Apollo Project brings together expertise and capital to find and help scale the most promising Covid-19 diagnostic opportunities. Originally funded under the leadership of RA Capital Management, the Project includes Redmile Group, Samsara BioCapital, Perceptive Advisors, and Bain Capital. “Returning to school and work requires sustainable testing solutions,” said Parker Cassidy, Principal at RA Capital Management and a member of Covid Apollo’s Board of Directors. “Covid Apollo is focused on finding and accelerating the most promising COVID testing solutions to rebuild testing paradigms to address the unique challenges that the pandemic has presented. Rhinostics is a great example of a company bringing new technologies and thinking to a segment of the laboratory workflow that is antiquated and ripe for innovation and acceleration.”
“The investment in Rhinostics is right on mission for Covid Apollo. With our investments, we are aiming to accelerate technologies that can immediately impact COVID testing, which still struggles to meet testing demand, while also providing new tests and diagnostic tools and processes to enable ubiquitous testing in the future, providing not only better pandemic protection and monitoring but also new testing paradigms, that will empower patients and consumers to live safer and healthier lives,” commented Stefan Willemsen, Chief Executive Officer of Covid Apollo. He adds that “the team at Rhinostics has rapidly executed on its strategic plan to bring their products to market, already providing significant volumes of product into COVID testing laboratories. We are excited to support their next phase of growth, commercialization and global impact on the pandemic.”
Rhinostics spun out of Harvard University to commercialize a novel automated nasal collection device invented in partnership by two Harvard faculty, Mike Springer, Associate Professor of Systems Biology at Harvard Medical School; and Richard Novak, Lead Staff Engineer at the Wyss Institute for Biologically Inspired Engineering. The novel nasal collection swab has features that can increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube while all 96 samples are simultaneously accessioned through scanning a 2D barcode on the bottom of the tubes. The product, registered as a Class I exempt medical device with the FDA, is currently being testing in several clinical trials, and the company is beginning an Emergency Use Authorization study comparing the RHINOstic™ swab to nasopharyngeal assays with a variety of polymerase chain reaction (PCR) assays. The product provides an immediate impact for increasing COVID testing efficiencies while being applicable to a broader range of respiratory viral, bacterial, and genetic testing using the PCR and next generation sequencing (NGS).
Cheri Walker, Chief Executive Officer of Rhinostics, commented, “We are thrilled to have Covid Apollo as a partner and investor to join our efforts to positively impact laboratory workflows and make a major impact on COVID testing volumes. Our missions are perfectly aligned to make a difference now. In addition, having Stefan as a board member will be a huge asset, as he is bringing more than 20 years of experience in leadership roles in the IVD industry to our fast-growing company, providing strategic advice and keen business insight. Together, we can change laboratory workflows for COVID and beyond.”
For decades there has been no innovation in viral collection and the process of moving samples into laboratories. The Rhinostics comfortable nasal swab solution brings new materials, better assay performance, dry shipment, instantaneous accessioning, and automated cap removal, all of which together can allow labs to significantly increase their sample throughput with no increase in footprint or staffing. This is changing the way laboratories think about their workflows.
About Covid Apollo Project
Covid Apollo Project aims to enable a safe and sustainable return to work and school by identifying, assembling, developing, and scaling the most promising COVID diagnostic opportunities. Covid Apollo was organized and funded under the leadership of RA Capital Management, a prominent biotechnology-focused investment firm, in collaboration with Redmile Group, Samsara BioCapital, Perceptive Advisors, and Bain Capital, and with legal support from Goodwin Procter. Covid Apollo is a funding founder of the $6M X-Prize competition to develop faster, cheaper and easier to use COVID testing methods at scale.
https://www.xprize.org/prizes/covidtesting
About Rhinostics
Rhinostics is revolutionizing laboratory workflows to link sample to result seamlessly. The company’s products improve sample collection performance while removing costs and time compared to traditional collection and intake. The products bring new materials, new collection types, rapid accessioning and automation to remove caps and move samples into high throughput workflows with little human intervention. The RHINOstic™ nasal swab provides features that increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube while all 96 samples are simultaneously accessioned through scanning a 2D barcode on the bottom of the tubes. The product provides an immediate impact to increasing COVID testing efficiencies while being applicable to broader respiratory viral, bacterial, and genetic testing using the polymerase chain reaction (PCR) and next generation sequencing (NGS). The RHINOstic™ product is registered as Class I exempt medical device with the FDA and is available for purchase. To learn more, visit https://www.rhinostics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005325/en/
Contact information
For Covid Apollo
Stefan Willemsen
swillemsen@covidapollo.com
(919) 525 8725
www.covidapollo.com
For Rhinostics Inc.
Cheri Walker
info@rhinostics.com
(877) 746-6789
www.rhinostics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra ® with MDR Certification and New Expanded Indication for Body5.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs, décolletage, and upper arms. Sculptra can be used across these areas to address varied treatment goals – from improving skin quality (including the improvement in cellulite appearance), to enhancing firmness, as well as lift, projection, and contouring.1-5 Sculptra’s versatility allows practitioners to meet each patient’s unique needs, delivering natural-looking, long-lasting improvements across face and body. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204988559/en/ Meeting the moment: evolving patient needs As aesthetic expectations shift, patients are seeking more holistic
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 03:40:00 EET | Press release
Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge formats designed for different group styles and expectat
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 02:00:00 EET | Press release
Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helical Fusion will further accelerate development under its flagship program, the Helix Program—a comprehensive roadmap to achieve the world’s first commercially viable fu
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Xsolla Integrates MVola as a Payment Method to Enable Instant, Card-Free Payments for Gamers in Madagascar’s Mobile-First Market4.12.2025 22:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced that MVola, Madagascar’s number one digital wallet, is now available as a payment option for players across the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204268075/en/ Chris Hewish, President of Xsolla Madagascar is a fast-growing, mobile-first market of 32 million people, where digital wallets are the primary driver of daily transactions. MVola, recently licensed as a digital bank, has established itself as the leading wallet in the country, with over 10 million users and powering more than 1 billion transactions annually. By adding MVola as a payment method to its portfolio, Xsolla removes the friction of card payments, enabling players to pay seamlessly with a trusted local method they already know and use every day. Key benefits of the MVola integration include: Instant confirmations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom